Lastly, TMB is lower but the PD-L1 expression trended higher in the NSCLC RET fusion-positive cohort when compared to the NSCLC RET fusion negative cohort, which suggests for further efficacy evaluation of ICPI in RET fusion positive NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.